SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer
Non-small cell lung cancers with inactivating SMARCA4 mutations are currently undruggable. Here, the authors show that the absence of SMARCA4/2 reduces chromatin accessibility at the CCND1 locus, leading to a subsequent reduction in cyclin D1 expression, which promotes vulnerability of these cancers...
Enregistré dans:
Auteurs principaux: | Yibo Xue, Brian Meehan, Zheng Fu, Xue Qing D. Wang, Pierre Olivier Fiset, Ralf Rieker, Cameron Levins, Tim Kong, Xianbing Zhu, Geneviève Morin, Lashanda Skerritt, Esther Herpel, Sriram Venneti, Daniel Martinez, Alexander R. Judkins, Sungmi Jung, Sophie Camilleri-Broet, Anne V. Gonzalez, Marie-Christine Guiot, William W. Lockwood, Jonathan D. Spicer, Abbas Agaimy, William A. Pastor, Josée Dostie, Janusz Rak, William D. Foulkes, Sidong Huang |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Nature Portfolio
2019
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/f919a450f672493c812a00c6c5045ab6 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
SMARCA4/2 loss inhibits chemotherapy-induced apoptosis by restricting IP3R3-mediated Ca2+ flux to mitochondria
par: Yibo Xue, et autres
Publié: (2021) -
CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary
par: Yibo Xue, et autres
Publié: (2019) -
Clinical impact of EZH2 and its antagonist SMARCA4 in ovarian cancer
par: Katharina Leitner, et autres
Publié: (2020) -
BET inhibitor suppresses migration of human hepatocellular carcinoma by inhibiting SMARCA4
par: Hae In Choi, et autres
Publié: (2021) -
SOX4 and SMARCA4 cooperatively regulate PI3k signaling through transcriptional activation of TGFBR2
par: Gaurav A. Mehta, et autres
Publié: (2021)